Actinogen Medical Limited Financial Analysis

This assignment analyzes the financial performance of Actinogen Medical Limited. It examines the company's comprehensive income statement, consolidated statement of financial position, and consolidated statement of cash flows to assess its profitability, asset management efficiency, and overall financial health. The analysis highlights areas where the company could improve its financial performance, such as reducing expenditure on research and development activities and optimizing asset turnover.

Financial Statement Analysis

EXECUTIVE SUMMARY
The present report is conducted to analyze the financial statement of Actinogen Ltd. The cited
organization is a pharmaceutical company involved in the development of drugs that treat
Alzheimer’s disease and other diseases like type-2 diabetes. With the growing life style changes,
the pharmaceutical industry has doubled its growth from 2009-10. The financial statements do
not display a good position of the company. Huge losses, negative cash flows, low liquidity
ratios, low EPS is part of the company’s statements over the years. The only strength of the
company lies in its efficient R&D department which is committed to giving innovative drugs to
treat the disease. The company has to work on many areas like maximizing shareholder’s wealth,
improving liquidity and profitability. The losses over the years have shown a decreasing trend
and are expected to pick up in the years to come.

Table of Contents
INTRODUCTION...........................................................................................................................6
INDUSTRY ANALYSIS AND COMPANY PLANS....................................................................6
Medical industry in Australia......................................................................................................6
Future plans of Actinogen Medicals............................................................................................7
FINANCIAL STATEMENT ANALYSIS......................................................................................7
Significant Accounting Policies..................................................................................................9
Trend Analysis...........................................................................................................................10
RATIO ANALYSIS......................................................................................................................11
Liquidity Ratios.........................................................................................................................11
Strengths....................................................................................................................................14
Weakness...................................................................................................................................14
RECOMMENDATIONS AND CONCLUSIONS........................................................................14
REFERENCES..............................................................................................................................15
APPENDICES...............................................................................................................................16

Table of figures
Figure 1: Position of revenue and loss in Actinogen Limited.......................................................11
Figure 2: Comprehensive Income Statement of Actinogen Ltd....................................................15
Figure 3: Consolidated Statement of Financial Position...............................................................16
Figure 4: Consolidated Statement of Cash flows..........................................................................16

List of Tables
Table 1: Common Balance Sheet for year 2016-2015.....................................................................7
Table 2: Financial Performance for the year 2015 and 2016...........................................................8
Table 3: Common Profit and Loss Statement for 2015 and 2016...................................................8
Table 4: Common Cash Flow Statement for year 2016-2015.........................................................9
Table 5: Analysis of Liquidity of Actinogen Ltd..........................................................................11
Table 6: Analysis of Profitability of Actinogen Ltd.....................................................................12
Table 7: Analysis of Cash flow adequacy of Actinogen Ltd.........................................................13

INTRODUCTION
Actinogen Medical is a biotechnology ASX-listed company which develops inventive
treatments for diseases like Alzheimer’s and metabolic diseases like Type 2 diabetes. The
management team includes world-renowned researchers in the field of Alzheimer’s disease and
also some industry specialists in clinical trial management and drug design. The present CEO of
the company is Dr Ketelbey, who has an experience of 30 years in the industry of healthcare and
pharmaceutical. Founded in 1999 the company has headquarters in New South Wales, Australia.
The company has shifted the office in Sydney with a view of expansion and growth. The
company is involved in developing a new approach to the production of drugs associated with
Alzheimer’s disease that slow down or even prevent the cognitive decline.
The latest fiscal year ended on 31st June 2016. The area of operation is expanded to
entire of Australia. The independent Auditor of the company as per the annual reports is Ernst &
Young. In their opinion, the statements reflect the true and fair picture of the financial position of
the company and are in compliance with AAS and Corporations Act 2001. The stock price of
Actinogen Medical as on 13th September 2017 was 0.052 AUD. The EPS according to the books
is 0.60 AUD [1].
INDUSTRY ANALYSIS AND COMPANY PLANS
Medical industry in Australia
As per the past surveys of 2010, there were around 12,545 people who were employed in
the manufacturing sector of medical technology (ABS, Experimental Estimates for the
Manufacturing Industry). The total of wages and salaries in the manufacturing outlets were
approximate $656 million for 2009-10, and the total value of production was around 2.1 Billion.
The data have just doubled itself at the end of 2015. Australia has been a leader in the
manufacturing of medicals, and its export market includes USA, New Zealand, UK, Germany;
Netherlands, Japan, China. Out of major exports include implants for disabilities and medical
treatments related to disabilities with growing age like Alzheimer’s disease. Hence, there are
great prospects for Actinogen Medical for growth and expansion in other countries as well [2].

Future plans of Actinogen Medicals
The major future plans of the company include conducting research on Xanamen- an
innovative drug used for the treatment of Alzheimer and communicating the results to different
communities of research and medical so that the findings of the research contribute to better
patient management. The company also plans to maximise shareholder’s wealth with the LTE
component [1].
FINANCIAL STATEMENT ANALYSIS
The tables below represent the company’s financial position as compared to the previous
year. The years prior to 2015 have not been considered for comparison as there no data is
available for the same.
Table 1: Common Balance Sheet for the year 2016-2015
Year 2016 2015
Assets
Current Assets 7744241.00 9805610.00
Increase / Decrease in percentage -21%
Non-Current Assets 5205312.00 5558178.00
Increase / Decrease in percentage -6%
Total Assets 12949553.00 15579248.00
Increase / Decrease in percentage -17%
Current Liabilities 783968.00 222640.00
Increase / Decrease in percentage 252%
Non-Current Liabilities - -
Increase / Decrease in percentage
Total Liabilities 783968.00 222640.00
Increase / Decrease in percentage 252%
Net Assets 12125350.00 15356608.00
Increase / Decrease in percentage -21%

Total Equity 26308391.00 2625489.00
Increase / Decrease in percentage 902%
Table 2: Financial Performance for the year 2015 and 2016
Year 2016 2015
Gross Profit - -
Increase / Decrease in percentage
Sales 3952943.00 153429.00
Increase / Decrease in percentage
Net loss -3633758.00 5431009.00
Increase / Decrease in percentage -167%
Table 3: Common Profit and Loss Statement for 2015 and 2016
Year 2016 2015
Revenue 204491.00 49927.00
Increase / Decrease in percentage 310%
Other Income 3748452.00 103502.00
Increase / Decrease in percentage 3522%
Expenses 7586701.00 5584438.00
Increase / Decrease in percentage 35.9%
loss before Income Tax -3633758 -5431009
Increase / Decrease in percentage -33.1%
Income Tax NA NA
Increase / Decrease in percentage -
Net profit after tax -3633758 -5431009

Increase / Decrease in percentage -33.1%
Other comprehensive income 22272.00 -
Increase / Decrease in percentage -
Total comprehensive Income -3611486.00 5431009.00
Increase / Decrease in percentage -166.5%
Table 4: Common Cash Flow Statement for the year 2016-2015
Year 2016 2015
Operating Cash Inflow -5039139.00 -3719789.00
Increase / Decrease in percentage 35%
Investing Cash Outflow -4014493.00 28446.00
Increase / Decrease in percentage -14213%
Financing Cash Outflow NA NA
Increase / Decrease in percentage
Net Decrease in Cash Held 751,978 9805610
Significant Accounting Policies
 Any transaction costs associated with equity are recognized directly under the
equity [3].
 The EPS is obtained by dividing the attributable profit, by the weighted average
number of ordinary shares outstanding during the financial year excluding any
costs of servicing equity. The amount obtained thereto is adjusted for a bonus in
ordinary shares issued.

 Other significant accounting policies like revenue recognition are accounted on
the basis of Effective Interest Rate Method in order to measure the values as
realizable over time.
 Current assets are measured initially at fair value and later at an amortized cost
[3].
 The trade receivables are due generally for the duration of 30 days after the
settlement.
Trend Analysis
The sales of the company have although increased to a great extent. However, Actinogen
still suffers from huge losses. There has not been any gross profit to the company. The
accumulated losses also include part of R&D activities, up to the extent of $2,605,395. Hence the
losses up to this amount can be justified. The other losses required to be assessed by the Board in
detail and appropriate manner. A downfall in the assets has been seen, and on the other hand,
there is an increase in liabilities as well. The company’s assets do not provide an adequate
backup to discharge any debts arising on account of the company.
The year 2016 has also seen a reduction in equity. This indicates that the company has
made cancellations of shares or repurchased its own shares in order to maximise shareholder’s
value. This provides a more efficient capital structure to the company and balances many ratios
which are currently not controllable by the management [4]. There were no financial inflows and
outflows of the company in 2016. However, the cash flow from financing activity also displayed
negative results in the previous year. The investing and operating cash flow remain negative;
however, the figures have seen major improvements, which are expected to rise further in the
coming years.

Figure 1: Position of revenue and loss in Actinogen Limited.
(Source: Annual Report. Actinogen Ltd. 2016.)
RATIO ANALYSIS
Liquidity Ratios
Table 5: Analysis of Liquidity of Actinogen Ltd.
Year 2016 2015
Working Capital Ratio 7744241/8242023 10021070/222640
(Current Assets/ Current Liabilities) 0.94 45.01
Average days sales uncollected 273.89 512.57
(Accounts Receivable/ Net Sales*365) 2966276/3952943*365 215460/153429*365
Current Ratio 7744241/8242023 10021070/222640
(Current Assets/ Current Liabilities) 0.94 45.01
Inventory Turnover ratio NA NA

Receivable turnover ratio NA NA
Avg Days Inventory in Hand NA NA
Liquidity ratios are calculated to ascertain the liquidity risk management of a particular
company [5]. In the case of Actinogin, the company follows an active mechanism to reduce the
risk of liquidity. The working capital ratio was very high in the year 2015 as compared to
previous year. This means there were idol funds which were far more than the amount actually
required [6]. This leads to overcapitalization of resources, which is not a very good situation for
any company which is striving for growth and expansion [7]. There is also the very high rate of
companies’ average day’s sales uncollected, due to which the current asset far exceed the current
liabilities.
Profitability Ratios
Table 6: Analysis of Profitability of Actinogen Ltd.
2016 2015
Profit Margin (3633755)/3952943 (5431009)/153429
(Profit / Sales) -0.92 -35.40
Asset Turnover Ratio 3952943/12949553 153429/15579248
(Net Sales / Total Assets) 0.31 0.41
Return on asset -3633755/12949553 -5431009/155279248
(Profit / Total Assets) -0.28 -0.03
Return on equity -3633755/1212350 -5431009/15356608
(Profit / Total Equity) [8] -3.00 -0.35
The company has witnessed major losses in consecutively two financial years. The losses
have increased due to large funding for expenses related to research and development. Other than
this another major reason for losses was an expense of share-based payment granted to Key

Management Personnel in the previous year. However, the company has an average Asset
Turnover ratio; it can still improve the ratio by proper asset management.
Long term Solvency Ratio
These ratios cannot be assessed and evaluated due to insufficient data.
Cash Flow adequacy
Table 7: Analysis of Cash flow adequacy of Actinogen Ltd.
2016 2015
Cash Flow Yield -5039139/(3952943) -5431009/(3719789)
(Cash Flow from operations /
Net profit)
-0.51 -1.46
Cash flow to assets 5039139/1426440.5
(Cash flow from operations /
Average Assets)
3.53 -
Cash flows to sales 5039139/3952943 5431009/153429
(Cash flow from operations /
Sales)
1.275 35.398
Free Cash Flow [9] - NA
The primary measure of measuring cash sufficiency is the Cash flow adequacy ratio. This
performance ratio should have a value of 1 or higher [10]. The company experiences a negative
ratio which indicates that the operations of the company do not produce sufficient cash for
meeting essential business debts. It also indicates potential problems of liquidity. It reflects the
company’s incapability of covering its debt repayment and capital expense [11].
Market strength ratios
2016 2015
Share price $0.08 NA
Earnings per share 0.6 1.32
Dividend - -

The EPS of the company has reduced significantly from the past year. Maximization of
shareholder’s wealth has been the future plan of the company, and the management is working to
improve the market strength thereby improving their share price in the years to come. Since the
date of incorporation, no amount has been paid by way of dividend.
Strengths
The major strength of the company lies in its Research and development activity which is
the major reason for the survival of the company in the competitive market despite incurring
huge losses over the years.
Weakness
The major weakness of the company is that the funds available with the company were
not being put to appropriate use, which may result in the loss of opportunity cost. Another area
of weakness is the negative cash outflows which fail to meet the major criteria required by a
company for being recognized as a strong performer.
RECOMMENDATIONS AND CONCLUSIONS
The company must work on its sales collection process, which will assist the company in
gaining a strong financial position in the market. It is also recommended for the company to
invest more effort in putting their idol resources to better use in expansion and growth beyond
the geographic territories of Australia. Asset management can be done in order to improve the
asset turnover ratio by a major focus on managing current assets like receivables [12]. The
operations of the business must be improved so that the cash flow position improves. Further, the
company must check the amount of expenditure in R&D activities.
According to the analysis of financial statements, it can be concluded that the company
does not reflect a good financial position. The company has a huge expenditure on R&D
activities, which form the major reason behind the losses. The company is incurring huge losses
due to which it can be said as a good performer.

REFERENCES
Online
ANNUAL FINANCIAL STATEMENTS. ACTINOGEN MEDICAL LIMITED. 2016. (PDF).
Available through < http://actinogen.com.au/wp-content/uploads/2017/07/20161024-Annual-
Report-to-Shareholders-1.pdf>. [Accessed on 14th September 2017.]
Books and Journal
David B, Wolfender JL, Dias DA. The pharmaceutical industry and natural products: historical
status and new trends. Phytochemistry Reviews. 2015 Apr 1,14(2). 299-315.
Duckett SJ, Breadon P, Ginnivan L, Venkataraman P. Australia's bad drug deal: high
pharmaceutical prices. Melbourne: Grattan Institute. 2013. Mar.
McLaney EJ, Atrill P. Accounting and Finance: An Introduction. Pearson. 2014.
Loughran T, McDonald B. Textual analysis in accounting and finance: A survey. Journal of
Accounting Research. 2016. Sep 1. 54(4). 1187-230.
Atrill P, McLaney E, Harvey D. Accounting: An Introduction, 6/E. Pearson Higher Education
AU. 2014. Aug 28.
Karaibrahimoglu YZ, Tunç G. Financial Statement Analysis under IFRS. InHandbook of
Research on Strategic Business Infrastructure Development and Contemporary Issues in
Finance. 2014. Feb 28. (Pp. 238-255). IGI Global.
Jose J. Customer Payment Trend Analysis Based on Clustering for Predicting the Financial Risk
of Business Organizations. Anchor Academic Publishing. 2017.
Bodie Z. Investments. McGraw-Hill. 2013.
Delen D, Kuzey C, Uyar A. Measuring firm performance using financial ratios: A decision tree
approach. Expert Systems with Applications. 2013. Aug 31. 40(10):3970-83.
Macve R. A Conceptual Framework for Financial Accounting and Reporting: Vision, Tool, Or
Threat?.sRoutledge. 2015. Dec 22.
Weil RL, Schipper K, Francis J. Financial accounting: an introduction to concepts, methods and
uses. Cengage Learning. 2013 Jan 29.

APPENDICES
Figure 2: Comprehensive Income Statement of Actinogen Ltd.

Figure 3: Consolidated Statement of Financial Position
Figure 4: Consolidated Statement of Cash flows